Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)GlobeNewsWire • 09/17/26
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses GoalsZacks Investment Research • 09/03/26
Ultragenyx's 'Fall From Grace' — Shares Crash 47%, Hitting A Record LowInvestors Business Daily • 09/03/26
Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet.Barrons • 09/03/26
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic DiseaseGlobeNewsWire • 09/01/26
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy GenglycosZacks Investment Research • 08/20/26
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a TranscriptSeeking Alpha • 08/20/26
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)GlobeNewsWire • 08/19/26
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/05/26